AMCP 2017 Abstracts Put Managed Care Pharmacy Research on Display in Denver
The AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017 brought managed care pharmacy research into a highly visible forum, with abstract presentations published in JMCP and scheduled across poster and podium sessions in Denver, Colorado. More than 2,000 managed care pharmacists and other health care professionals were expected to attend the meeting, reflecting the breadth of the audience that shapes drug therapy access, benefit design, and medication-use decisions across managed care programs.
The meeting abstracts supplement served as more than a conference add-on. It functioned as a formal record of applied pharmacy work, giving investigators a venue to share outcomes, operational strategies, and practice insights that matter directly to how therapies are selected, managed, and monitored in real-world systems. In managed care, the value of evidence is often measured not only by biologic efficacy, but by whether a therapy can be integrated into networks, formularies, and medication management processes without compromising access or safety.
Poster presentations were scheduled for Tuesday, March 28, from 5:45 pm to 7:30 pm, with posters displayed again on Wednesday, March 29, from 11:45 am to 2:45 pm. Podium presentations for the Platinum award-winning abstracts followed on Wednesday afternoon from 4:30 pm to 5:45 pm. The structure created multiple opportunities for attendees to engage with abstract authors, compare practice models, and evaluate which interventions may scale across managed care settings.
One sentence captures the central clinical purpose of the meeting: these abstracts were designed to move pharmacy practice closer to measurable patient benefit.
Managed care pharmacy occupies a distinct position in the health system because it sits between evidence generation and therapeutic delivery. Pharmacists in this field do not simply review medications; they influence how drugs are covered, which populations receive them first, how specialty therapies are monitored, and how benefit structures affect adherence and outcomes. The AMCP annual meeting offered a concentrated snapshot of that work, with authors presenting insights drawn from advanced managed care practice and published in a supplement dedicated to the field.
The Denver meeting also reporting how specialty pharmacy has become inseparable from modern managed care. Specialty drugs often carry high costs, complex administration requirements, and narrow therapeutic windows, which forces health plans and pharmacy teams to balance clinical urgency with utilization management. A meeting built around abstract presentations in this setting naturally attracts interest from professionals responsible for evaluating drug therapy, developing and managing networks, and coordinating with medical managers and information specialists.
The supplement format mattered because it extended the reach of the meeting beyond the conference floor. Publication in JMCP placed the abstracts into a peer-reviewed professional channel, allowing managed care pharmacy findings to circulate among clinicians and administrators who may not have attended the sessions in person. In a field where policy, formulary operations, and patient access are tightly linked, even brief abstract-level evidence can influence how organizations think about implementation.
The conference’s emphasis on advanced managed care practice also reflected the expanding workload of pharmacists in integrated care systems. These professionals increasingly work across medication therapy management, specialty drug oversight, network development, and data-driven evaluation of outcomes. As the meeting program suggested, the abstract sessions were intended to showcase the kind of applied research that helps organizations refine those responsibilities in day-to-day practice.
A second sentence stands out because it frames the stakes plainly: managed care pharmacy research affects whether patients get the right therapy through the right channel at the right time.
Although the material available for the meeting announcement did not enumerate individual study results, the abstract supplement itself signals a field in active motion. Conferences like AMCP’s annual meeting give shape to the questions that matter in real systems: how to evaluate therapies, how to compare utilization strategies, and how to design pharmacy programs that can support both clinical quality and operational efficiency. Those questions are especially pressing in specialty pharmacy, where costs and complexity are high and the consequences of delayed or fragmented access can be immediate.
For health care organizations, the practical significance of the Denver meeting lies in translation. Abstracts presented in this environment are not isolated academic exercises; they are often the first public step in moving a practice innovation into broader use. A pharmacy benefit approach, a care coordination model, or a network-management strategy may begin as a poster and later shape organizational policy if the evidence is persuasive enough.
By gathering a large national audience, AMCP created a setting where evidence could be tested against the realities of managed care. That process remains central to pharmacy practice: not every intervention that works in a controlled environment survives the demands of coverage decisions, patient navigation, and specialty medication oversight. The annual meeting abstract supplement offered a venue for those ideas to be debated, compared, and refined in public.
The Denver program ultimately pointed to a familiar challenge in managed care pharmacy: turning abstract findings into operational change without losing sight of patient care. The supplement documented the work, but the next step depended on how health systems, plans, and pharmacy leaders interpreted and implemented the evidence presented there.